AltheaDx Drops IPO Plans

San Diego-based molecular diagnostics developer AltheaDX has dropped its plans for an IPO, saying in a SEC filing Monday that it is withdrawing its S-1 and does not plan to pursue its IPO. AltheaDx--which originally filed confidentially for an IPO in July of 2014, and revealed its plans in December, said in its filing that the terms on the public marketplace are "not sufficiently attractive" to the company. AltheaDx had originally planned to IPO on the NASDAQ Global Market as IDGX. The company is venture backed by Telegraph Hill Partners and Alma Life Sciences.